An attempt to eliminate bias in the interpretation of clinical trial outcomes. It indicates that at least one party involved in the clinical trial is unaware of which patients are receiving the experimental treatment and which are receiving the control substance. Trials may be either single blind (patients do not know which treatment they are receiving) or double-blind (neither the examining physicians nor the patients know which treatment each patient is receiving).